Background: Glioblastoma is an aggressive malignant brain tumor with exceptionally poor prognosis. Currently, patients with this diagnosis receive a combination of chemotherapy, surgical debulking, as well as radiation therapy. Recently, a new device has been FDA approved for treatment of glioblastoma called the NovoTTF-100A system. Research has shown improvement of patients’ lives as well as prolonged survival. The focus of this systematic review is to evaluate if the NovoTTF-100A system could be an effective addition to the standard of care for patients with glioblastoma.
Methods: An exhaustive medical literature search was completed using MEDLINE-Ovid, Web of Science, and Google Scholar. The keyword used was Novo-TTF100A system. The quality of the selected articles were assessed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system.
Results: Of the 83 articles screened in the initial search, only 2 met the criteria for review. Both of the selected studies showed prolonged median overall survival for patients treated with NovoTTF-100A therapy, whether that be alone or in combination with other front line treatments. One study was low quality, and the other was very low quality when using the GRADE system.
Conclusion: The NovoTTF-100A system is associated with positive outcomes in the treatment of glioblastoma. No significant adverse events were recorded with the use of this therapy, only some localized skin irritation. The NovoTTF-100A therapy does seem to be beneficial to patients with glioblastoma, but further research needs to be done to find out which patients would and would not benefit as much from the therapy.
Keywords: NovoTTF-100A, Glioblastoma
|File name||Date Uploaded||Visibility||File size|